Payment overview · 2025
General Payments
$216.26
11 reported records · 6 companies
Healthcare provider profile · identity verified
Narendra Kutnikar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MONROE, LA · NPI 1497742175
Verified facts
What the public records show
CMS Open Payments records show Narendra Kutnikar, MD received $216.26 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.50 | 29.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.83 | 21.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.75 | 17.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.40 | 15.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.11 | 9.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.67 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $216.26 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $63.50 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $45.83 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $37.75 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $36.78 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 143 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
143 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 764 | 99 |
| Atorvastatin Calcium | Atorvastatin Calcium | 326 | 91 |
| Tramadol Hcl | Tramadol Hcl | 318 | 53 |
| Omeprazole | Omeprazole | 302 | 86 |
| Gabapentin | Gabapentin | 298 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 269 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 231 | 60 |
| Metformin Hcl | Metformin Hcl | 178 | 54 |
| Losartan Potassium | Losartan Potassium | 161 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 158 | 44 |
| Carvedilol | Carvedilol | 148 | 44 |
| Ozempic | Semaglutide | 143 | 33 |
| Furosemide | Furosemide | 138 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 133 | 51 |
| Montelukast Sodium | Montelukast Sodium | 131 | 42 |
| Lisinopril | Lisinopril | 122 | 30 |
| Eliquis | Apixaban | 113 | 26 |
| Prednisone | Prednisone | 111 | 44 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 105 | 32 |
| Trazodone Hcl | Trazodone Hcl | 102 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 37 |
| Azithromycin | Azithromycin | 97 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 91 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 88 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 87 | suppressed |
| Potassium Chloride | Potassium Chloride | 79 | 33 |
| Doxazosin Mesylate | Doxazosin Mesylate | 78 | 25 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 78 | 36 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 76 | 57 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 26 |
| Spironolactone | Spironolactone | 76 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 22 |
| Clonidine Hcl | Clonidine Hcl | 74 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 21 |
| Nifedipine Er | Nifedipine | 74 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 18 |
| Donepezil Hcl | Donepezil Hcl | 60 | 19 |
| Meloxicam | Meloxicam | 57 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 19 |
| Kerendia | Finerenone | 55 | suppressed |
| Memantine Hcl | Memantine Hcl | 54 | 15 |
| Ezetimibe | Ezetimibe | 53 | 17 |
| Linzess | Linaclotide | 53 | 21 |
| Pregabalin | Pregabalin | 52 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 51 | 21 |
| Tresiba Flextouch U-200 | Insulin Degludec | 49 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 21 |
| Fluconazole | Fluconazole | 45 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 34 |
| Amiodarone Hcl | Amiodarone Hcl | 41 | 13 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 16 |
| Jardiance | Empagliflozin | 39 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 35 | 12 |
| Clonazepam | Clonazepam | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Sotalol | Sotalol Hcl | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 24 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | 11 |
| Baclofen | Baclofen | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $216.26 · 11 records | AstraZeneca Pharmaceuticals LP | BREZTRI, FREESTYLE LIBRE 3, JARDIANCE, Ozempic, Rybelsus, TRELEGY ELLIPTA, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error